Campath-1H Induction to Allow Discontinuation of Calcineurin Inhibitors After Renal Transplantation

Completed · Not applicable

Conditions studied: Primary Renal Transplant

In brief

The purpose of this study is to determine whether Campath-1H induction therapy and the associated lymphocyte depletion will permit long-term, rejection free renal allograft function in the absence of maintenance calcineurin inhibitor (CI) therapy.

Key facts

Study ID

NCT00214201

Run by

University of Wisconsin, Madison

People needed

40

Starts

2003-05-01

Expected to finish

2009-05-01

Last updated by the study team

2012-10-03

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• received a renal transplant, induction with Campath-1H, and at least 2 months of calcineurin inhibitor therapy, CellCept, and prednisone.

You may not qualify if…

• Recipients of HLA-identical living-donor renal transplants;
• PRA value >20% within 30 days of transplant;
• GFR <40ml/min;
• multi-organ transplant;

Where it is running

• University of Wisconsin — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.